OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-995-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$44.42 million
Profitability
Miscellaneous
Employees22
Next Earnings DateN/A
OptionableOptionable
Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions
What is Oncomed Pharmaceuticals' stock symbol?
Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."
How were Oncomed Pharmaceuticals' earnings last quarter?
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) posted its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.16 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.36. The biopharmaceutical company had revenue of $19.52 million for the quarter, compared to analysts' expectations of $7.97 million. Oncomed Pharmaceuticals had a negative net margin of 18.24% and a negative return on equity of 13.14%. View Oncomed Pharmaceuticals' Earnings History.
What price target have analysts set for OMED?
2 Wall Street analysts have issued twelve-month price targets for Oncomed Pharmaceuticals' stock. Their predictions range from $1.50 to $2.00. On average, they anticipate Oncomed Pharmaceuticals' stock price to reach $1.75 in the next year. This suggests a possible upside of 96.6% from the stock's current price. View Analyst Price Targets for Oncomed Pharmaceuticals.
What is the consensus analysts' recommendation for Oncomed Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncomed Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Oncomed Pharmaceuticals.
Has Oncomed Pharmaceuticals been receiving favorable news coverage?
Media headlines about OMED stock have been trending negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Oncomed Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Oncomed Pharmaceuticals.
Who are some of Oncomed Pharmaceuticals' key competitors?
Some companies that are related to Oncomed Pharmaceuticals include IDEAYA Biosciences (IDYA), Paratek Pharmaceuticals (PRTK), Bicycle Therapeutics (BCYC), BioXcel Therapeutics (BTAI), Mersana Therapeutics (MRSN), Harrow Health (HROW), Generex Biotechnology (GNBT), ProMetic Life Sciences (PFSCF), Humanigen (HGEN), Northwest Biotherapeutics (NWBO), Abeona Therapeutics (ABEO), Corvus Pharmaceuticals (CRVS), CELYAD SA/ADR (CYAD), AgeX Therapeutics (AGE) and Scpharmaceuticals (SCPH).
What other stocks do shareholders of Oncomed Pharmaceuticals own?
Who are Oncomed Pharmaceuticals' key executives?
Oncomed Pharmaceuticals' management team includes the folowing people:
- Mr. Perry A. Karsen, Exec. Chairman (Age 64)
- Ms. Jill Henrich, Sr. VP of Regulatory Affairs & Quality Assurance
- Dr. Ann Kapoun Ph.D., Sr. VP of Translational Medicine
What is Oncomed Pharmaceuticals' stock price today?
One share of OMED stock can currently be purchased for approximately $0.89.
How big of a company is Oncomed Pharmaceuticals?
Oncomed Pharmaceuticals has a market capitalization of $34.43 million and generates $44.42 million in revenue each year. The biopharmaceutical company earns $-8,100,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Oncomed Pharmaceuticals employs 22 workers across the globe.View Additional Information About Oncomed Pharmaceuticals.
What is Oncomed Pharmaceuticals' official website?
How can I contact Oncomed Pharmaceuticals?
Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]
MarketBeat Community Rating for Oncomed Pharmaceuticals (NASDAQ OMED)
MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
